Beam Therapeutics (BEAM) Debt Ratio (2019 - 2026)

Beam Therapeutics (BEAM) posted quarterly Debt Ratio of 0.07 for Q1 2026, up 3692.27% quarter-over-quarter from 0.0 in Q4 2025.

Analysis

Beam Therapeutics (BEAM) Debt Ratio (2019 - 2026) Analysis & Trends

Beam Therapeutics (BEAM) has reported Debt Ratio for 2 consecutive years, with 0.07 the latest figure, recorded in Q1 2026.

In Q1 2026, Debt Ratio changed N/A year-over-year to 0.07; the TTM figure through Mar 2026 stood at 0.07 (changed N/A YoY), while the FY2025 annual figure was 0.0, changed N/A from the prior year.
Debt Ratio advanced to 0.07 in Q1 2026 per BEAM's latest filing, from 0.0 in the prior quarter.
Across five years, Debt Ratio topped out at 0.07 in Q1 2026 and bottomed at 0.0 in Q3 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	0.05
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	0.05
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	0.12
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	0.47
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	0.26
10	Beam Therapeutics	3.10 Bn	3.10 Bn	-	0.08

Historic Data

Download Data